Squamous Cell Carcinoma of the Esophagus

2018 ◽  
Author(s):  
Kyle G Mitchell ◽  
David B Nelson ◽  
Wayne L Hofstetter
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Treatment Options ◽  
Gastroesophageal Junction ◽  
Careful Consideration ◽  
Western World ◽  
Esophageal Diseases ◽  
Trimodality Therapy ◽  
Carcinoma Of The Esophagus

Although its incidence in the Western world is decreasing, squamous cell carcinoma of the esophagus (ESCC) remains a significant cause of cancer mortality worldwide. Recent analyses have identified a number of unique characteristics that differentiate ESCC from esophageal adenocarcinoma at the etiologic, genomic, and epigenetic levels. A thorough diagnostic and staging work-up includes endoscopy, endoscopic ultrasonography, and axial imaging. Applicable therapeutic modalities include definitive endoscopic therapies, resection alone, trimodality therapy, definitive chemoradiation, systemic therapy, and palliative treatment options. Given the complexity of this disease and its management, careful consideration in a multidisciplinary setting is warranted to appropriately individualize therapeutic options. This review contains 5 figures, 6 tables, and 51 references. Key Words: squamous cell carcinoma, esophageal diseases, esophageal cancer, esophageal neoplasms, gastroesophageal junction, Tylosis, bimodality therapy, trimodality therapy, endoscopic therapy

Squamous Cell Carcinoma of the Esophagus

2018 ◽  
Author(s):  
Kyle G Mitchell ◽  
David B Nelson ◽  
Wayne L Hofstetter
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Treatment Options ◽  
Gastroesophageal Junction ◽  
Careful Consideration ◽  
Western World ◽  
Esophageal Diseases ◽  
Trimodality Therapy ◽  
Carcinoma Of The Esophagus

Although its incidence in the Western world is decreasing, squamous cell carcinoma of the esophagus (ESCC) remains a significant cause of cancer mortality worldwide. Recent analyses have identified a number of unique characteristics that differentiate ESCC from esophageal adenocarcinoma at the etiologic, genomic, and epigenetic levels. A thorough diagnostic and staging work-up includes endoscopy, endoscopic ultrasonography, and axial imaging. Applicable therapeutic modalities include definitive endoscopic therapies, resection alone, trimodality therapy, definitive chemoradiation, systemic therapy, and palliative treatment options. Given the complexity of this disease and its management, careful consideration in a multidisciplinary setting is warranted to appropriately individualize therapeutic options. This review contains 5 figures, 6 tables, and 51 references. Key Words: squamous cell carcinoma, esophageal diseases, esophageal cancer, esophageal neoplasms, gastroesophageal junction, Tylosis, bimodality therapy, trimodality therapy, endoscopic therapy

A randomized clinical trial evaluating the efficacy and safety of the addition of oral metronomic chemotherapy after completion of standard chemoradiation versus observation in patients with locally advanced esophageal and gastroesophageal junction squamous cell carcinoma.

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. 163-163
Author(s):  
Vanita Noronha ◽  
Vijay Maruti Patil ◽  
Amit Joshi ◽  
Nandini Sharrel Menon ◽  
Supriya Goud ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Induction Chemotherapy ◽  
Phase Ii ◽  
Squamous Cell ◽  
Gastroesophageal Junction ◽  
Locally Advanced ◽  
Metronomic Chemotherapy ◽  
Carcinoma Of The Esophagus

163 Background: In RTOG 85-01, patients with locally advanced esophageal and gastroesophageal junction (GEJ) cancer treated with concurrent chemoradiotherapy (CRT) had a median overall survival (OS) of 14 months and 5-year OS of 27%. Improving outcomes in these patients is an unmet need. We investigated the addition of oral metronomic chemotherapy (OMC) following definitive CRT. Methods: A randomized integrated phase II/III clinical trial (CTRI/2015/09/006204) in patients with squamous cell carcinoma of the esophagus or the GEJ who had completed definitive radical CRT within the past 12 weeks, had an ECOG PS 0-2 and no clinical or radiologic evidence of progressive disease. Patients were stratified based on whether or not they had received induction chemotherapy followed by CRT, and then randomized 1:1 to receive OMC (celecoxib 200 mg twice daily and methotrexate 15 mg/m2 weekly) for 12 months or observation. The primary efficacy endpoint for the phase II portion was progression free survival (PFS). The secondary endpoints were OS and toxicity. With a power of 70% and an alpha of 10%, we hypothesized a hazard ratio of 1.5, with a median follow-up of 6 months. The planned sample size for the phase II portion was 151 patients. The p-value for stopping the trial after the phase II part of the study was set at 0.2 for the PFS. Results: Between Jan 2016 and Dec 2019, we enrolled 151 patients, 75 to the OMC arm and 76 to observation. The median age was 57 years, 59% were male. The tumor originated in the upper thoracic esophagus in 79% patients, with median tumor length 6 cm. Induction chemotherapy was received by 14% of the patients. Concurrent CRT consisted of median 63 Gy in median 35 fractions; 91% patients received concurrent weekly paclitaxel and carboplatin with radiation. OMC was started at a median of 11 weeks (IQR, 9 to 12) from the start of CRT. Grade 3 or higher toxicities (regardless of relatedness to study intervention) were noted in 27 patients (17.9%), 18 in the OMC arm and 9 in the observation arm; P=0.071. The median time to disease progression or death was 23 months (95% CI, 7.9-38.1) in the OMC arm and not reached in the observation arm; HR, 1.33, 95% CI, 0.83-2.14; P=0.23. The 1-year PFS was 67% in both the arms; the 2-year PFS were 48% and 61% in the OMC and observation arms respectively. The median OS was 36 months (95% CI, 17.9-54) in the OMC arm and not reached in the observation arm; HR, 1.75; 95% CI, 1.02-2.99; P, 0.037. The 1-year OS was 74.7% in the OMC arm and 88% in the observation arm; the 2-year OS was 53.9% in the OMC arm and 75% in the observation arm. Conclusion: Adjuvant oral metronomic chemotherapy after radical CRT does not improve outcomes in patients with locally advanced esophageal or GEJ squamous cell carcinoma. Clinical trial information: CTRI/2015/09/006204.

scholarly journals Squamous cell carcinoma of the scrotum in HIV: two case reports

2021 ◽  
Vol 27 (1) ◽  
Author(s):  
Jeff John ◽  
Ken Kesner ◽  
John Lazarus
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Case Reports ◽  
Treatment Options ◽  
Punch Biopsy ◽  
Delayed Treatment ◽  
Clinical Presentations ◽  
T1 N0 M0

Abstract Background Squamous cell carcinoma (SCC) of the scrotum was the first malignancy known to be associated with exposure to an occupational carcinogen—in this case, soot trapped in the breeches of chimney sweeps. Better civil rules and regulations and the replacement of hearths with other forms of heating have rendered SCC of the scrotum a rarity. We report two cases of scrotal SCC with vastly differing clinical presentations and management. Case presentation Case 1 had T1 N0 M0 disease and presented with a small (< 2 cm), innocuous-looking, non-healing ulcer of eight years duration. A punch biopsy revealed a superficially invasive SCC confirmed on immunohistochemical profiling. A wide local excision of the lesion was subsequently performed. Follow-up at three years showed no signs of recurrence. Case 2 presented with T4 N1 M1 disease and rapidly progressing locally destructive mass. A punch biopsy of the scrotal lesion confirmed invasive moderately differentiated focally keratinising SCC. The metastatic evaluation confirmed the presence of metastatic, extensive para-aortic lymphadenopathy. He was managed with cisplatin-based chemoradiotherapy. Conclusion Early detection and management of patients with SCC of the scrotum are essential. If the diagnosis is delayed, treatment options become limited, and the prognosis is poor. Notwithstanding the rarity of this disease, multicentre trials are needed to provide more precise guidelines as to the optimal management of these patients.

scholarly journals Chemotherapy alone versus definitive concurrent chemoradiotherapy for cT4b esophageal squamous cell carcinoma: a population-based study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Chia-Chin Li ◽  
Chih-Yi Chen ◽  
Ying-Hsiang Chou ◽  
Chih-Jen Huang ◽  
Hsiu-Ying Ku ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Concurrent Chemoradiotherapy ◽  
Statistical Significance ◽  
Treatment Options ◽  
Population Based ◽  
Primary Analysis

Abstract Background The role of radiotherapy for cT4bNanyM0 esophageal squamous cell carcinoma (ESqCC) is relatively unclear, with both chemotherapy (C/T) alone and definitive concurrent chemoradiotherapy (dCCRT) being treatment options in the current guidelines. We aimed to compare the survival of dCCRT versus C/T for these patients via a population-based approach. Methods Eligible cT4b ESqCC patients diagnosed between 2011 and 2017 were identified via the Taiwan Cancer Registry. We used propensity score (PS) weighting to balance the observable potential confounders between groups. The hazard ratio (HR) of death and incidence of esophageal cancer mortality (IECM) were compared between dCCRT and C/T. We also evaluated OS in subgroups of either low or standard radiotherapy doses. Results Our primary analysis consisted of 247 patients in whom covariates were well balanced after PS weighing. The HR for death when dCCRT was compared with C/T was 0.36 (95% confidence interval 0.24–0.53, P < 0.001). Similar results were found for IECM. Statistical significance was only observed in the standard RT dose but not in the low dose in subgroup analyses. Conclusions In this population-based nonrandomized study of cT4bNanyM0 ESqCC patients from Asia (Taiwan), we found that the use of radiotherapy with chemotherapy was associated with better overall survival than chemotherapy alone. Further studies (especially RCTs) are needed to confirm our findings.

p53 Overexpression in squamous cell carcinoma of the esophagus

1997 ◽  
Vol 4 (1) ◽  
pp. 37-45 ◽  
Author(s):  
Paul L. Baron ◽  
Christopher E. Gates ◽  
Carolyn E. Reed ◽  
Roberta L. D. Dikeman ◽  
Jay J. Drosieko ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
P53 Overexpression ◽  
Carcinoma Of The Esophagus

Tu1673 Usefulness of Magnified Endoscopy With NBI for Diagnosing the Depth of Invasion of Squamous Cell Carcinoma of the Esophagus

2012 ◽  
Vol 75 (4) ◽  
pp. AB484
Author(s):  
Toshiro Iizuka ◽  
Daisuke Kikuchi ◽  
Akihiro Yamada ◽  
Osamu Ogawa ◽  
Masanori Nakamura ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Depth Of Invasion ◽  
Carcinoma Of The Esophagus ◽  
Magnified Endoscopy

Local recurrence of squamous-cell carcinoma of the esophagus after EMR

2005 ◽  
Vol 61 (2) ◽  
pp. 219-225 ◽  
Author(s):  
Chikatoshi Katada ◽  
Manabu Muto ◽  
Tetsuro Manabe ◽  
Atsushi Ohtsu ◽  
Shigeaki Yoshida
Keyword(s):  
Squamous Cell Carcinoma ◽  
Local Recurrence ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Carcinoma Of The Esophagus

Su1821 A Risk Factor Predictive of Serious Laryngeal Edema During Endoscopic Resection for Squamous Cell Carcinoma of the Esophagus

2013 ◽  
Vol 144 (5) ◽  
pp. S-482
Author(s):  
Nobuyuki Ara ◽  
Kaname Uno ◽  
Naoki Asano ◽  
Katsunori Iijima ◽  
Tomoyuki Koike ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Risk Factor ◽  
Cell Carcinoma ◽  
Endoscopic Resection ◽  
Squamous Cell ◽  
Laryngeal Edema ◽  
Carcinoma Of The Esophagus

Cardiac tamponade as an unusual initial presentation of squamous cell carcinoma of the esophagus

2021 ◽  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Cancer ◽  
Pericardial Effusion ◽  
Cell Carcinoma ◽  
Cardiac Tamponade ◽  
Squamous Cell ◽  
Unknown Etiology ◽  
Thoracic Esophagus ◽  
Moderate Amount ◽  
Carcinoma Of The Esophagus

Pericardial effusions leading to cardiac tamponade have previously been described with esophageal cancer. However, up to eighty percent of these cases have been reported in association with chemotherapy and radiation. Patients with esophageal cancer seldom initially present with pericardial effusion resulting from esophageal pericardial fistula (EPF). Herein, we present the case of a 62-year-old man who presented with pericardial effusion with an unknown etiology at presentation. Subsequently, the patient developed cardiac tamponade and was referred to the tertiary hospital for further evaluation. Computed tomography of the chest revealed a circumferential irregular enhancing lesion at the mid-thoracic esophagus suspecting esophageal cancer with EPF and a moderate amount of pericardial effusion. The patient underwent esophagoscopy and squamous cell carcinoma was found from the esophageal biopsy. An esophageal stent was successfully placed to conceal the perforation. Eventually, the patient died 13 days after admission complicated by refractory septic shock. This case highlights an atypical presentation of esophageal cancer and an unusual cause of cardiac tamponade.

Sign in / Sign up

Export Citation Format

Share Document